

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/517,518  
Applicant : Stefan SPERL  
Filed : December 13, 2004  
TC/A.U. :  
Examiner :

Docket No. : 2923-671  
Customer No. : 6449  
Confirmation No. :

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450


Sir:

In compliance with applicants duty of disclosure under 37 C.F.R. 1.56, enclosed is a copy of the International Search Report in the corresponding international application. The relevance of the references is noted in the International Search Report. We understand that the references have been forwarded by the International Bureau, and are available to the Examiner, but if the Examiner needs copies of any of the references, the Examiner is requested to advise counsel accordingly.

In the event that any fees are due with this paper, please charge our Deposit Account No. 02-2135.

Respectfully submitted,

By



Robert B. Murray  
Attorney for Applicant  
Registration No. 22,980  
ROTHWELL, FIGG, ERNST & MANBECK  
1425 K. Street, Suite 800  
Washington, D.C. 20005  
Telephone: (202) 783-6040

RBM/cb

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<i>Complete if Known</i>	
				Application Number	10/517,518
				Filing Date	December 3, 2004
				First Named Inventor	Stefan SPERL
				Group Art Unit	
				Examiner Name	
				Confirmation No.	
Sheet	1	of	2	Attorney Docket Number	2923-671

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
	1.	WO	02/074756	A	Pentapham AG	9/26/02	
	2.	WO	00/04954	A	Stuerzebecher et al	2/3/00	
	3.	DE	199 40 389	A	Wilex Biotechnology GmbH	3/1/01	
	4.	DE	100 29 014	A	Univ Schiller Jena	12/20/01	
	5.	WO	01/070204	A	Max Planck	9/27/01	
Examiner Signature					Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*Complete if Known*

Application Number	10/517,518
Filing Date	December 3, 2004
First Named Inventor	Stefan SPERL
Group Art Unit	
Examiner Name	
Confirmation No.	

Sheet

2

of

2

Attorney Docket Number 2923-671

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	6.	Sturzebecher et al., "3-Amidinophenylalanine-based inhibitors of Urokinase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 21, November 1, 1999, pgs. 3147-3152.	
	7.	Magdolen et al., "Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator", "ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 477, 2000, pgs. 331-341.	
	8.	Heechung et al., "Selective Inhibition of Urokinase by Substituted Phenylguanidines:...", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 33, no. 11, 1990, pgs. 2956-2961.	
	9.	Sperl et al., "(4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 97, no. 10, 9 May 2000, pgs. 5113-5118.	
	10.	Nienaber et al., "Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 10, 10 March 2000, pgs. 7239-7248.	
Examiner Signature			Date Considered